AstraZeneca plc LSE&NYSE&OMX: AZN p. farmaceutyczny m.in leki onkologiczne, COVID

[slayer74]

AstraZeneca (LON:AZN) (NASDAQ:AZN) stock rose 2.6% after the drugmaker said its cancer drug, Enhertu, delayed the progression of a form of advanced breast cancer in previously treated patients, boosting prospects of more regulatory approvals.

[slayer74]

British drugmaker AstraZeneca (NASDAQ:AZN) following upbeat earnings.

AstraZeneca gained 1.4% as it raised its full-year adjusted earnings forecast after beating expectations for quarterly profit and revenue.

[slayer74]

LON:AZN) stock fell 0.9% after the U.K.-based drugs giant announced plans to buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma (NASDAQ:CINC) in a deal valued at about $1.8 billion.

[slayer74]

AstraZeneca (LON:AZN) stock rose 3.9% after the drugmaker beat expectations with fourth-quarter profits, despite lower-than-expected sales of its best-selling oncology and rare blood disorder drugs plus a decline in sales of its COVID-19 vaccine.

[slayer74]

AstraZeneca – The FTSE 100’s Number 1 by Market Capitalisation

AstraZeneca the pharmaceutical giant is the largest FTSE 100 share by market capitalisation. The stock currently has a market valuation of £177.7 billion. AstraZeneca is a British-Swedish multinational company, with its headquarters in Cambridge, UK.

The stock has seen tremendous rates of return, 5 years a go the stock was changing hands for around £47, currently the shares are worth around £111. The rate of return over the last 5 years has been a staggering 136.4%.

Whilst the stock does not possess a large dividend yield, it currently stands around 2%, the stock still has potential growth. Whilst it is unlikely that we will see the same returns in the next 5 years, as we have in the last 5 years, there is certainly confidence in AstraZeneca.

The graph below shows the 5 year performance:



Whilst there have been evidential dips over the last 5 years, you can clearly see the upward journey that this stock has taken. When we look at the analyst projections for AstraZeneca, the average price target is £118, but the high price target is £135. Price targets should always be taken with absolute caution, but I think that the stock is a good longterm hold, with still potential for an upwards trajectory in share price, alongside the dividend income.

https://ftsedividends.co.uk/index.php/2 ... alisation/

[slayer74]

AstraZeneca (LON:AZN) stock rose 0.9% after the drugmaker beat expectations for its first-quarter profit and revenue, helped by sales of its roster of drugs in emerging markets.

[slayer74]

LONDON (Reuters) -AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.

AstraZeneca (NASDAQ:AZN) decided not to continue its membership after a recent assessment of whether it was "the most productive and effective use of (company) resources", a spokesperson for the British drugmaker said in an emailed statement.

PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023.

The news, first reported by Politico, marks the trade body's third major departure in six months. AstraZeneca's exit follows those of AbbVie (NYSE:ABBV), maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs.

AstraZeneca will redirect the funds previously used on its PhRMA membership to continue U.S. advocacy efforts with state and federal policymakers, its statement read.

The U.S. is the largest national market for all big pharma companies. Drugmakers suffered a rare defeat last year in failing to stop the Inflation Reduction Act, which allows the government to negotiate prices on certain drugs.

[slayer74]

AstraZeneca retreated following a Financial Times report the pharmaceuticals giant is planning to spin off its China business and considering a separate unit listing in Hong Kong.

[slayer74]

AstraZeneca shares fell as results from a high-level study of a new cancer medicine raised worries the drug might not work as well as anticipated.

[slayer74]

AstraZeneca (NASDAQ:AZN) ADRs rose pre 1.2% after UBS upgraded its stance on the pharma giant to ‘buy’ from ‘neutral’, saying its hefty drug pipeline makes it "a leading player in the field."

[slayer74]

AstraZeneca Q2 results beat estimates; COVID vaccine sales dry up

LONDON (Reuters) -AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of COVID-19 vaccine sales.

Shares in the Anglo-Swedish drugmaker, which has a strong line-up of cancer, metabolic and rare disease drugs, rose as much as 4.8%, before settling back to 3.9% by 1052 GMT, making the stock the largest weighted gainer on the FTSE 100.

Sentiment was boosted by Chief Executive Pascal Soriot's positive remarks on the company's data from a key lung cancer trial, an AstraZeneca (NASDAQ:AZN) shareholder and an analyst told Reuters.

Speaking to the media after second-quarter results, which showed a 25% rise in earnings, Soriot said the company is "very encouraged" by interim data from the TROPION-Lung01 trial, but he did not explain why the company had not declared results as "clinically meaningful".

Shares in AstraZeneca fell by as much by 8% earlier this month after interim data from the TROPION trial on an experimental precision drug called datopotamab deruxtecan, which disappointed investors.

The company said on Friday it will continue with its plan to file data from the trial with the U.S. drug regulator, soothing some concerns.

Markus Manns, a senior portfolio manager at Union Investment and AstraZeneca shareholder, said that “should increase investor confidence in the product”, after underwhelming interim data.

The strong results, which showed an adjusted profit of $2.15 per share, up 25% and exceeding the $1.98 per share expected in a company-compiled consensus, add to a string of strong quarters for the UK's biggest company by market capitalisation worth more than 165 billion pounds ($211 billion), bolstered by a strong pipeline of drugs.

Even so, the company registered no sales of its COVID-19 vaccine, its best-selling product in 2021 at the height of the pandemic, compared with $445 million a year ago, and said it expects sales to decline significantly in the full year.

SATISFIED WITH CHINA STRUCTURE

The rapid decline of the COVID business for one of the first drugmakers to develop a shot against the virus in 2020 highlights the challenge in competing with rival vaccines manufactured by Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA).

"Each of our non-COVID-19 therapy areas saw double-digit revenue growth, with eight medicines delivering more than $1bn of revenue in the first half, demonstrating the strength of our business," Soriot said.

Excluding COVID medicines, sales in China grew by 7% at constant exchange rates in the quarter, the fourth consecutive quarter of growth on that basis.

The company upgraded its guidance for China, saying it expected total revenue to grow by a low-to-mid single digit percentage in 2023, up from a low single-digit percentage increase.

AstraZeneca is the largest drugmaker in China, which accounted for 13% of last year's revenue.

According to an FT report in June, the drugmaker was drafting a plan to spin off its China business, and considering listing a separate unit in Hong Kong.

On Friday's call with journalists, Soriot responded to a question about that report by dismissing it as a "rumour". "We are satisfied with the way we are structured in China today and our focus is delivering those medicines to patients and partnering with local biotech companies in particular."

AstraZeneca stood by its 2023 outlook.

Separately, the company said on Friday its unit Alexion (NASDAQ:ALXN) has agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales to bolster its genomic medicine capabilities.

[slayer74]

AstraZeneca was higher after announcing positive results from the TROPION-Breast01 phase three trial on Friday.